Evidence map›Paper›PMID 38075165›Full record

ArticleAdvances in laboratory medicine2023

Recurrent genetic variants and prioritization of variants of uncertain clinical significance associated with hereditary breast and ovarian cancer in families from the Region of Murcia.

Laura Rosado-Jiménez, Younes Mestre-Terkemani, Ángeles García-Aliaga, Miguel Marín-Vera, José Antonio Macías-Cerrolaza, María Desamparados Sarabia-Meseguer, María Rosario García-Hernández, Marta Zafra-Poves, Pilar Sánchez-Henarejos, Francisco Ayala de la Peña and 3 more

Open access · diamondAbstract read
In one paragraph

Article in Advances in laboratory medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Identification and Computational Analysis ofMedical sciences (Basel, Switzerland) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Laura Rosado-JiménezGenomics Laboratory, Department Service of Clinical Laboratory Analysis, Clinical University Hospital Virgen de la Arrixaca, Murcia, Spain.
Younes Mestre-TerkemaniGenomics Laboratory, Department Service of Clinical Laboratory Analysis, Clinical University Hospital Virgen de la Arrixaca, Murcia, Spain.
Ángeles García-AliagaGenomics Laboratory, Department Service of Clinical Laboratory Analysis, Clinical University Hospital Virgen de la Arrixaca, Murcia, Spain.
Miguel Marín-VeraService of Medical Oncology, Virgen de la Arrixaca University Hospital, Murcia, Spain.
José Antonio Macías-CerrolazaDepartment of Medical Oncology, Clinical University Hospital Morales Meseguer, Murcia, Spain.
María Desamparados Sarabia-MeseguerGenomics Laboratory, Department Service of Clinical Laboratory Analysis, Clinical University Hospital Virgen de la Arrixaca, Murcia, Spain.
María Rosario García-HernándezService of Medical Oncology, Virgen de la Arrixaca University Hospital, Murcia, Spain.
Marta Zafra-PovesDepartment of Medical Oncology, Clinical University Hospital Morales Meseguer, Murcia, Spain.
Pilar Sánchez-HenarejosService of Medical Oncology, Virgen de la Arrixaca University Hospital, Murcia, Spain.
Francisco Ayala de la PeñaDepartment of Medical Oncology, Clinical University Hospital Morales Meseguer, Murcia, Spain.
José Luis Alonso-RomeroService of Medical Oncology, Virgen de la Arrixaca University Hospital, Murcia, Spain.
José Antonio Noguera-VelascoGenomics Laboratory, Department Service of Clinical Laboratory Analysis, Clinical University Hospital Virgen de la Arrixaca, Murcia, Spain.
Francisco Ruiz-EspejoGenomics Laboratory, Department Service of Clinical Laboratory Analysis, Clinical University Hospital Virgen de la Arrixaca, Murcia, Spain.
Hospital Universitario Virgen de la Arrixaca · ESHospital General Universitario Morales Meseguer · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Hereditary breast and ovarian cancer (HBOC) follows an autosomal dominant inheritance pattern of cancer susceptibility genes. The risk of developing this disease is primarily associated with germline mutations in the Methods: A prevalence study of HBOC was performed within 2,928 families from the Region of Murcia, in southeastern Spain. Genetic testing enabled the identification of recurrent pathogenic variants and founder mutations, which were mainly related to the Results: Variants c.68_69del, c.212+1G>A, and c.5123C>A were detected in 30 % of Conclusions: The genotype-phenotype correlation observed in our study is consistent with the scientific literature. Furthermore, the founder effect of c.1918C>T (

Indexed as

founder effecthereditary breast and ovarian cancermutational spectrumprioritizationrecurrent pathogenic variantsvariants of uncertain clinical significance

Identifiers

PMID38075165
PMCPMC10701504
OpenAlexW4386934960

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.